Portrait of Teresa M. Darragh
ucsf logo

Teresa M. Darragh, MD

Anatomic Pathology • Obstetrics and Gynecology
Portrait of Teresa M. Darragh
Portrait of Teresa M. Darragh
ucsf logo

Teresa M. Darragh, MD

Anatomic Pathology • Obstetrics and Gynecology

On this page

About me

Dr. Teresa M. Darragh is a pathologist who specializes in anogenital neoplasia (including cervical and anal cancer) induced by human papillomavirus (HPV).

In her research, Darragh investigates HPV-related anogenital tract disease in men and women. UCSF's team of experts has been fundamental in the medical field's recognition of anal HPV-related disease and its acceptance of anal cytology as a screening tool for at-risk populations.

Darragh earned her medical degree at Weill Cornell Medicine. At UCSF, she completed a residency in pathology, followed by fellowships in cytopathology and surgical pathology.

Darragh is a member of several professional organizations, including the American Society for Clinical Pathology, Papanicolaou Society of Cytopathology, American Society of Cytopathology, College of American Pathologists and American Society for Colposcopy and Cervical Pathology (ASCCP). She has received numerous honors, including an award of merit for scientific achievement from ASCCP.

Education & training

Board certification

  • Cytopathology, American Board of Pathology
  • Anatomic Pathology, American Board of Pathology

Residency

  • Anatomic/Clinical Pathology, UCSF Medical Center House Staff

Degree

  • MD, Cornell University at Ithaca

My expertise

My research

Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.